Multiple Sclerosis: Where Do We Go From Here? - European Medical Journal

Multiple Sclerosis: Where Do We Go From Here?

Download PDF
*Marta Tejera-Alhambra,1 Lidia Fernández-Paredes,2 Clara de Andrés,3 Silvia Sánchez-Ramón2

The authors have declared no conflicts of interest.


Our acknowledgment to Fundación Mapfre, Fundación Salud 2000, Fondo de Investigación Sanitaria, and the European Research Council Starting Award for their support.

EMJ Neurol. ;4[1]:84-95. DOI/10.33590/emjneurol/10313951.
Multiple sclerosis (MS), biomarkers, clinical activity

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Multiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal, social, and economic public health burden. The clinical course and response of MS to therapy is highly heterogeneous, but most patients progress from a relapsing-remitting disease course, in which patients may respond to immunomodulatory drugs, to a steady progression and neurodegeneration that is unresponsive to any currently available treatment. In the last few years, novel disease-modifying therapies for MS have become available but the aetiology of the disease remains an enigma. The search for clinical biomarkers that are able to stratify MS patients and allow the personalisation of treatment strategies, has developed greatly in recent years though only a few have been integrated into routine clinical practice.

Please view the full content in the PDF above. 

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally